Market Cap 82.65M
Revenue (ttm) 0.00
Net Income (ttm) -33.85M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 198,675
Avg Vol 895,602
Day's Range N/A - N/A
Shares Out 60.33M
Stochastic %K 23%
Beta 1.20
Analysts Strong Sell
Price Target $6.25

Company Profile

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally admini...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 761 4904
Fax: 339 674 6495
Address:
131 Hartwell Avenue, Suite 320, Lexington, United States
DavidScott
DavidScott Sep. 15 at 2:57 AM
On watch tomorrow (swing trading) // Part 2 🔥📈📚 $CLOV $ALDX $ASST $SOUN $FUBO
0 · Reply
DavidScott
DavidScott Sep. 14 at 7:55 PM
$LHSW $CLOV $ALDX $ASST $SOUN = Great work! The bulls here continue to be strong. Let's keep putting the pressure on these bears some more tomorrow! These were our team's best moves, and we are bullish and expecting even more momentum on these names again going into Tuesday. If you need any guidance or a mentor, then feel free to join our team anytime! ✅🙌 Have a great day everybody! 🎉
0 · Reply
MingChoo
MingChoo Sep. 13 at 9:46 PM
$ALDX eyeing this.23
0 · Reply
Vladxccc
Vladxccc Sep. 11 at 6:10 PM
$ALDX big pos wth
0 · Reply
Noah808
Noah808 Sep. 11 at 2:25 AM
$ALDX Patience will finally pay off after type D minutes are released, hopefully soon.
0 · Reply
Merlintrader
Merlintrader Sep. 4 at 11:24 AM
$ALDX Aldeyra Therapeutics Stock Hub: Can the FDA Type D Meeting Reopen a Path for Reproxalap and AbbVie Optionality? https://www.merlintrader.com/aldeyra-therapeutics-stock-hub/
1 · Reply
Biorocksme
Biorocksme Sep. 2 at 3:34 AM
$ALDX total waste of everything. lol. 💩
0 · Reply
Milanfinest
Milanfinest Sep. 1 at 6:55 PM
$ALDX sometimes i come back just to remember what means losing time
1 · Reply
philipv777
philipv777 Aug. 31 at 11:49 AM
$ALDX man, holding on this is an exercise in patience (but hopefully not futility)...
1 · Reply
steven1x
steven1x Aug. 29 at 4:01 PM
$ALDX when’s the merger ….lol Ms. Deptula-Hicks is a senior biotechnology executive with over 30 years of experience across public and private life science companies, spanning therapeutics, diagnostics, medical devices, and emerging healthcare technologies. She has held senior executive, chief financial officer, board roles, and has extensive experience supporting companies through initial public offerings, major capital raises, strategic partnerships, and M&A transactions. Ms. Deptula-Hicks currently serves as the acting Chief Financial Officer of Normunity Inc., a clinical-stage biotech company focused on novel therapies to treat cancer. Previously, she served as Chief Financial Officer of F-star Therapeutics, Inc. Ms. Deptula-Hicks holds an M.B.A. from Rivier University and a B.S. in Accounting from Southern New Hampshire University.
0 · Reply
Latest News on ALDX
Aldeyra Therapeutics Quarterly report: Q2 2026

Aug 6, 2026, 7:00 AM EDT - 6 weeks ago

Aldeyra Therapeutics Quarterly report: Q2 2026


Levicept Appoints Darlene Deptula-Hicks as CFO

Jul 7, 2026, 4:00 AM EDT - 2 months ago

Levicept Appoints Darlene Deptula-Hicks as CFO


Shareholders Sue Aldeyra Therapeutics Over Dry Eye Drug Claims

2026-05-27T09:59:56.000Z - 3 months ago

Shareholders Sue Aldeyra Therapeutics Over Dry Eye Drug Claims


Aldeyra Therapeutics Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 4 months ago

Aldeyra Therapeutics Quarterly report: Q1 2026


Aldeyra Therapeutics Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Aldeyra Therapeutics Proxy statement: Proxy filing


Aldeyra Therapeutics Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Aldeyra Therapeutics Proxy statement: Proxy filing


Aldeyra downgraded to Neutral from Buy at H.C. Wainwright

2026-03-18T10:12:28.000Z - 6 months ago

Aldeyra downgraded to Neutral from Buy at H.C. Wainwright


US FDA declines to approve Aldeyra's drug for eye disorder

Mar 17, 2026, 8:36 AM EDT - 6 months ago

US FDA declines to approve Aldeyra's drug for eye disorder


Aldeyra Therapeutics Annual report: Q4 2025

Feb 27, 2026, 7:00 AM EST - 6 months ago

Aldeyra Therapeutics Annual report: Q4 2025


Aldeyra Therapeutics Slides: Corporate Presentation

Dec 16, 2025, 6:00 PM EST - 9 months ago

Aldeyra Therapeutics Slides: Corporate Presentation


Aldeyra Therapeutics Transcript: Study Update

Dec 16, 2025, 8:00 AM EST - 9 months ago

Aldeyra Therapeutics Transcript: Study Update


Aldeyra Therapeutics Press release: Study Update

Dec 16, 2025, 8:00 AM EST - 9 months ago

Aldeyra Therapeutics Press release: Study Update


Aldeyra announces PDUFA extension for Reproxalap

2025-12-16T01:05:11.000Z - 9 months ago

Aldeyra announces PDUFA extension for Reproxalap


Aldeyra Therapeutics Transcript: R&D Day 2025

Nov 13, 2025, 8:00 AM EST - 10 months ago

Aldeyra Therapeutics Transcript: R&D Day 2025


Aldeyra Therapeutics Press release: FY 2025

Nov 13, 2025, 8:00 AM EST - 10 months ago

Aldeyra Therapeutics Press release: FY 2025


Aldeyra Therapeutics Slides: FY 2025

Nov 13, 2025, 8:00 AM EST - 10 months ago

Aldeyra Therapeutics Slides: FY 2025


Aldeyra expands RASP platform

2025-11-13T12:46:13.000Z - 10 months ago

Aldeyra expands RASP platform


Aldeyra Therapeutics Slides: Corporate Presentation

Nov 6, 2025, 7:00 AM EST - 10 months ago

Aldeyra Therapeutics Slides: Corporate Presentation


Aldeyra Therapeutics Quarterly report: Q3 2025

Nov 5, 2025, 4:00 PM EST - 10 months ago

Aldeyra Therapeutics Quarterly report: Q3 2025


Aldeyra price target raised to $7 from $6 at Jefferies

2025-10-08T16:50:12.000Z - 11 months ago

Aldeyra price target raised to $7 from $6 at Jefferies

ABBV


Aldeyra receives orphan designation from EMA for ADX-2191

2025-08-28T11:16:06.000Z - 1 year ago

Aldeyra receives orphan designation from EMA for ADX-2191


Aldeyra granted fast track designation for ADX-2191 by FDA

2025-08-19T11:16:08.000Z - 1 year ago

Aldeyra granted fast track designation for ADX-2191 by FDA


Aldeyra Therapeutics Slides: Corporate Presentation

Aug 8, 2025, 4:00 PM EDT - 1 year ago

Aldeyra Therapeutics Slides: Corporate Presentation


Aldeyra Therapeutics Quarterly report: Q2 2025

Aug 7, 2025, 7:00 AM EDT - 1 year ago

Aldeyra Therapeutics Quarterly report: Q2 2025


Aldeyra receives orphan designation for ADX-2191 from EMA

2025-07-24T11:26:18.000Z - 1 year ago

Aldeyra receives orphan designation for ADX-2191 from EMA


Aldeyra Therapeutics Slides: Corporate Presentation

Jun 25, 2025, 7:00 AM EDT - 1 year ago

Aldeyra Therapeutics Slides: Corporate Presentation


Aldeyra resubmits topical ocular reproxalap NDA to FDA

2025-06-17T11:10:56.000Z - 1 year ago

Aldeyra resubmits topical ocular reproxalap NDA to FDA


Aldeyra Therapeutics Quarterly report: Q1 2025

May 14, 2025, 4:00 PM EDT - 1 year ago

Aldeyra Therapeutics Quarterly report: Q1 2025


Aldeyra Therapeutics Transcript: Study Update

May 6, 2025, 8:00 AM EDT - 1 year ago

Aldeyra Therapeutics Transcript: Study Update


Aldeyra Therapeutics Slides: Study Update

May 6, 2025, 8:00 AM EDT - 1 year ago

Aldeyra Therapeutics Slides: Study Update


DavidScott
DavidScott Sep. 15 at 2:57 AM
On watch tomorrow (swing trading) // Part 2 🔥📈📚 $CLOV $ALDX $ASST $SOUN $FUBO
0 · Reply
DavidScott
DavidScott Sep. 14 at 7:55 PM
$LHSW $CLOV $ALDX $ASST $SOUN = Great work! The bulls here continue to be strong. Let's keep putting the pressure on these bears some more tomorrow! These were our team's best moves, and we are bullish and expecting even more momentum on these names again going into Tuesday. If you need any guidance or a mentor, then feel free to join our team anytime! ✅🙌 Have a great day everybody! 🎉
0 · Reply
MingChoo
MingChoo Sep. 13 at 9:46 PM
$ALDX eyeing this.23
0 · Reply
Vladxccc
Vladxccc Sep. 11 at 6:10 PM
$ALDX big pos wth
0 · Reply
Noah808
Noah808 Sep. 11 at 2:25 AM
$ALDX Patience will finally pay off after type D minutes are released, hopefully soon.
0 · Reply
Merlintrader
Merlintrader Sep. 4 at 11:24 AM
$ALDX Aldeyra Therapeutics Stock Hub: Can the FDA Type D Meeting Reopen a Path for Reproxalap and AbbVie Optionality? https://www.merlintrader.com/aldeyra-therapeutics-stock-hub/
1 · Reply
Biorocksme
Biorocksme Sep. 2 at 3:34 AM
$ALDX total waste of everything. lol. 💩
0 · Reply
Milanfinest
Milanfinest Sep. 1 at 6:55 PM
$ALDX sometimes i come back just to remember what means losing time
1 · Reply
philipv777
philipv777 Aug. 31 at 11:49 AM
$ALDX man, holding on this is an exercise in patience (but hopefully not futility)...
1 · Reply
steven1x
steven1x Aug. 29 at 4:01 PM
$ALDX when’s the merger ….lol Ms. Deptula-Hicks is a senior biotechnology executive with over 30 years of experience across public and private life science companies, spanning therapeutics, diagnostics, medical devices, and emerging healthcare technologies. She has held senior executive, chief financial officer, board roles, and has extensive experience supporting companies through initial public offerings, major capital raises, strategic partnerships, and M&A transactions. Ms. Deptula-Hicks currently serves as the acting Chief Financial Officer of Normunity Inc., a clinical-stage biotech company focused on novel therapies to treat cancer. Previously, she served as Chief Financial Officer of F-star Therapeutics, Inc. Ms. Deptula-Hicks holds an M.B.A. from Rivier University and a B.S. in Accounting from Southern New Hampshire University.
0 · Reply
MewKitty
MewKitty Aug. 28 at 4:29 AM
$ALDX FYI - LEGAL UPDATE per ChatGPT-5: Judge Levenson issued a Memorandum & Order Aug 10, 2026 Massachusetts Federal District Court, docket # 1:26‑cv‑11510 - S. Albonico appointed lead plaintiff, highest estimated loss >300K - Orrell and Bustamante motions are DENIED for lead plaintiff, lower losses - Rosen Law Firm approved as lead counsel per lead plaintiff request - ALDX has retained Goodwin Procter LLP for legal defense. Both Rosen & GP are heavy hitters in securities fraud. - Scheduling Order (Aug 11–12, 2026) set the litigation calendar: TIMELINE: Amended/Expanded Complaint - Oct 9, 2026 - Access it through PACER Defendants’ Answer or Motion to Dismiss - Dec 8, 2026 Plaintiff Opposition to Motion to Dismiss - Jan 22, 2027 Defendants' Reply - Feb 22, 2027 Stay tuned - GLTA
0 · Reply
prismmarketview
prismmarketview Aug. 26 at 2:41 PM
Bausch + Lomb is taking its dual-action dry eye drop to Phase 3 after a Phase 2 study told it when to measure. The combination showed a significant improvement over Xiidra alone at Day 15, ahead of the Day 29 timepoint the company had originally chosen. The FDA accepts Day 15 for registrational studies, so the pivotal program will be built around it. In dry eye, knowing when to measure can matter as much as what you are measuring. Aldeyra, Palatin and OKYO are each working through their own version of that question. $BLCO $ALDX $PTN $OKYO https://prismmarketview.com/bausch-lomb-missed-its-dry-eye-endpoint-the-result-still-points-to-phase-3/
0 · Reply
RigidFlexibility
RigidFlexibility Aug. 25 at 7:25 PM
$ALDX …quiet in here. At a LOSS…..for words? Heavy bags here. Sold only a little to buy other prospects. C’mon CEO, say something. Or not. Lol. Lord, bring us back from the dead please. GLTA.
3 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Aug. 19 at 7:24 PM
$ALDX I think a resolution on this regulatory saga may be closer than the market thinks. Asymmetric risk-reward (but still significant downside risk given a current market valuation 2x cash). My summary for anyone interested: https://substack.com/@biotechpharmainvestor/note/c-318286245?r=2nece1&utm_source=notes-share-action&utm_medium=web
0 · Reply
philipv777
philipv777 Aug. 19 at 4:54 PM
$ALDX as far as I understand, aldeyra should currently be getting their ducks in a row for an FDR/appeal. The likelihood of an agreement with the FDA without the FDR is very unlikely. Im sure lawyers are heavily involved which would explain why Todd didn't jump straight to FDR aftr last type a and went w/ this 'type D' to tie up loose ends. This desperately needs some direction; the limbo (especially after FOUR total CRL's) has left this with ZERO credibility and im not sure Type D will really resolve all my concerns at this point but it's a start.
1 · Reply
PeterV9764
PeterV9764 Aug. 18 at 5:23 PM
$ALDX Philip I wouldn’t be surprised if we get some sort of news by next week! I take that as a good sign
1 · Reply
philipv777
philipv777 Aug. 18 at 3:43 PM
$ALDX something’s cookin!
1 · Reply
DavidScott
DavidScott Aug. 17 at 3:19 AM
On watch tomorrow (swing trading) // Part 2 🔥📈📚 $NMAX $BYND $INO $ALDX $CAN
0 · Reply
DavidScott
DavidScott Aug. 14 at 8:00 PM
$ONFO $NMAX $INO $BYND $ALDX = Great job bulls! It was a solid session today for these movers (especially with some of these choppy conditions). These were our team's best trades this round! We are bullish and expecting even more action on these names again going into Monday. If you need any guidance or a mentor, then feel free to join our team anytime! ✅🤝 Have a great weekend everyone! 🎉
1 · Reply
VoxGeorge
VoxGeorge Aug. 13 at 11:06 PM
1 · Reply